Atezolizumab plus bevacizumab for advanced, unresectable hepatocellular carcinoma.
Publication
, Journal Article
Tsilimigras, D; Moris, D
Published in: Journal of B.U.ON. : official journal of the Balkan Union of Oncology
March 2021
Duke Scholars
Published In
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
EISSN
2241-6293
ISSN
1107-0625
Publication Date
March 2021
Volume
26
Issue
2
Start / End Page
637
Related Subject Headings
- Oncology & Carcinogenesis
- Neoplasm Staging
- Liver Neoplasms
- Humans
- Carcinoma, Hepatocellular
- Bevacizumab
- Antineoplastic Combined Chemotherapy Protocols
- Antibodies, Monoclonal, Humanized
Citation
APA
Chicago
ICMJE
MLA
NLM
Tsilimigras, D., & Moris, D. (2021). Atezolizumab plus bevacizumab for advanced, unresectable hepatocellular carcinoma. Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology, 26(2), 637.
Tsilimigras, Diamantis, and Dimitrios Moris. “Atezolizumab plus bevacizumab for advanced, unresectable hepatocellular carcinoma.” Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology 26, no. 2 (March 2021): 637.
Tsilimigras D, Moris D. Atezolizumab plus bevacizumab for advanced, unresectable hepatocellular carcinoma. Journal of BUON : official journal of the Balkan Union of Oncology. 2021 Mar;26(2):637.
Tsilimigras, Diamantis, and Dimitrios Moris. “Atezolizumab plus bevacizumab for advanced, unresectable hepatocellular carcinoma.” Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology, vol. 26, no. 2, Mar. 2021, p. 637.
Tsilimigras D, Moris D. Atezolizumab plus bevacizumab for advanced, unresectable hepatocellular carcinoma. Journal of BUON : official journal of the Balkan Union of Oncology. 2021 Mar;26(2):637.
Published In
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
EISSN
2241-6293
ISSN
1107-0625
Publication Date
March 2021
Volume
26
Issue
2
Start / End Page
637
Related Subject Headings
- Oncology & Carcinogenesis
- Neoplasm Staging
- Liver Neoplasms
- Humans
- Carcinoma, Hepatocellular
- Bevacizumab
- Antineoplastic Combined Chemotherapy Protocols
- Antibodies, Monoclonal, Humanized